MANTECH Publications

Journal of Homoeopathic Pharmacy Research
Volume 2, Issue 1, January-June 2025

Comparative In-Vitro Cytotoxicity Study of Homeopathic Nosodes and Allopathic Counterparts on Human Cancer Cell Lines

Dr. Sangeeta Kumari[1], Rakesh Narayan[2]

Associate Professor[1], Student[2]

Department of Organon of Medicine[1], Department of Pharmacology[2]

Sri Sainath Post Graduate Institute of Homoeopathy, Allahabad, Uttar Pradesh

Email ID: *drsangeetakumari1@gmail.com[1]*

Abstract

Nosodes, derived from pathological tissues or disease products, represent one of the most controversial and understudied branches of homeopathic pharmacy. In contrast to conventional allopathic vaccines or chemotherapeutic agents, nosodes claim therapeutic benefits without cytotoxic effects. This study aims to assess the cytotoxic potential of Carcinosin, Tuberculinum, and Medorrhinum nosodes on MCF-7 (breast cancer), HeLa (cervical cancer), and A549 (lung cancer) human cell lines, in comparison with standard chemotherapeutic agents like Doxorubicin and Cisplatin. Using MTT assays, flow cytometry, and reactive oxygen species (ROS) assays, the study demonstrates minimal cytotoxicity of nosodes while indicating a potential immunomodulatory effect as reflected in cytokine stimulation and apoptotic marker expression. The results offer insight into the potential for integrating nosodes as adjuvant therapies in oncology, especially for palliative care patients sensitive to chemotherapy toxicity. The study recommends deeper exploration of epigenetic influence and biofield interaction facilitated by potentized nosodes.

Keywords*: Homeopathic nosodes, Carcinosin, Tuberculinum, cancer cell lines, cytotoxicity, MTT assay, ROS modulation, apoptosis, complementary oncology, palliative treatment.*

INTRODUCTION

The application of homeopathy in complex diseases such as cancer has remained a subject of debate, largely due to the lack of empirical and mechanistic validation. Within the realm of homeopathic pharmacy, **nosodes**—remedies prepared from diseased tissues, microbial cultures, or pathological secretions—are among the most controversial and least understood. Unlike allopathic chemotherapeutic agents, nosodes are administered in high dilutions and are believed to work on the principle of **informational therapeutics**, potentially stimulating the body's immune system without causing cytotoxic damage.

The increasing interest in **integrative oncology** has necessitated deeper investigations into non-toxic, supportive remedies that may complement standard treatments, particularly for **palliative care patients** or individuals with low drug tolerance. This study aims to compare the **in-vitro cytotoxicity of three widely used homeopathic nosodes—Carcinosin, Tuberculinum, and Medorrhinum—against conventional allopathic agents such as Doxorubicin and Cisplatin** on cancer cell lines MCF-7 (breast), HeLa (cervical), and A549 (lung).

By employing validated techniques such as **MTT assays**, **flow cytometry**, and **reactive oxygen species (ROS)** detection, we aim to determine whether nosodes induce any direct cytotoxic or apoptotic effect on cancer cells and if they hold potential for further exploration in **complementary cancer treatment protocols**.

LITERATURE REVIEW

Homeopathic Nosodes: A Historical Overview

Nosodes have been used since the late 19th century, starting with Psorinum prepared by Dr. Samuel Hahnemann. Unlike conventional drugs that target cellular biochemistry, nosodes are believed to operate via bioenergetic pathways, subtly stimulating host defense mechanisms without molecular toxicity. Despite their long use, **scientific validation has been minimal**, with few peer-reviewed studies detailing their biological or pharmacodynamic actions.

Cytotoxicity in Cancer Therapy

Conventional chemotherapeutic agents such as Doxorubicin and Cisplatin exert their effects by disrupting cell replication, inducing apoptosis, and elevating oxidative stress. While these

drugs are effective, they are **notoriously toxic**, causing severe side effects in healthy tissues. There is growing interest in identifying **adjuvant or alternative approaches** that are less damaging to non-cancerous cells, and which may act **synergistically with standard therapy**.

Emerging Evidence on Nosodes

Preliminary studies, including work by Khuda-Bukhsh et al. (2014), have demonstrated gene expression modulation and apoptosis-regulating effects of homeopathic remedies in cancer cell lines. However, these results remain contentious due to the high dilutions used and lack of reproducible models. Nonetheless, **nosodes offer promise as immunomodulatory agents** that could potentially enhance host resistance without contributing to tumor cell cytotoxicity.

MATERIALS AND METHODS

Nosode and Drug Preparation

- **Homeopathic Nosodes**:

  Carcinosin (200C)

  Tuberculinum (200C)

  Medorrhinum(200C)

  These were obtained from a GMP-certified homeopathic manufacturer and verified for potency through batch number and serial dilution protocol.

- **Allopathic Drugs**:

  Doxorubicin

  Cisplatin

  Both agents were sourced in pure form and prepared in sterile PBS at working concentrations (1 µM–10 µM).

Table 1: Cell Culture Lines

Cell Line	Origin	Culture Medium
MCF-7	Human breast	RPMI-1640 + 10% FBS
HeLa	Cervical cancer	DMEM + 10% FBS
A549	Lung carcinoma	F12-K + 10% FBS

Cells were cultured in a 5% CO_2 incubator at 37°C, sub-cultured every 48–72 hours.

Experimental Conditions

- **MTT Assay**: 96-well plates were seeded with 10^4 cells/well. After 24-hour adherence, treatments were applied and viability was measured after 48 hours using MTT reagent.
- **Flow Cytometry**: Annexin V-FITC and Propidium Iodide were used to evaluate apoptotic and necrotic cells.
- **ROS Assay**: DCFH-DA fluorescent dye was used to assess intracellular ROS levels.
- **Controls**: Vehicle controls (alcohol solvent) were included to rule out carrier effects.



Figure 1: Experimental Workflow Overview

Description:

A flowchart illustrating the step-by-step experimental process:

- Selection of remedies and drugs
- Cell culture (MCF-7, HeLa, A549)
- Treatment groups (Nosodes, Allopathic drugs, Controls)

- Assays used (MTT, Flow Cytometry, ROS)

RESULTS

Table: 2 MTT Assay: Cell Viability Post-Treatment

Treatment	MCF-7 Viability (%)	HeLa Viability (%)	A549 Viability (%)
Doxorubicin (1 µM)	28	35	32
Cisplatin (1 µM)	24	38	30
Carcinosin (200C)	92	89	91
Tuberculinum (200C)	94	87	93
Medorrhinum (200C)	93	88	90
Vehicle Control	96	95	95

Explanation: Chemotherapeutic drugs caused significant cytotoxicity, reducing cell viability to below 40%. In contrast, nosodes retained **cell viability above 85%**, similar to vehicle controls, indicating **non-cytotoxic behavior.**



Figure 2: Cell Viability (%): Mtt Assay Results

Description:

Bar chart showing % viability of MCF-7, HeLa, and A549 cells after treatment with:

- Carcinosin
- Tuberculinum

- Medorrhinum
- Doxorubicin
- Cisplatin
- Vehicle Control

Table 3: Flow Cytometry: Apoptosis Induction

Treatment	% Early Apoptosis	% Late Apoptosis	% Necrosis
Doxorubicin	42	30	15
Cisplatin	40	32	17
Carcinosin	5	3	2
Tuberculinum	6	4	1
Medorrhinum	4	3	1
Vehicle Control	3	2	1

Explanation: Allopathic agents induced apoptosis significantly, while nosodes showed only mild effects, statistically similar to controls. This suggests nosodes may **not act through direct apoptotic mechanisms**.



Figure 3: Apoptotic Profile from Flow Cytometry

Description: Grouped bar chart showing % of early apoptosis, late apoptosis, and necrosis across treatments.

Table 4: ROS Assay: Oxidative Stress Modulation

Treatment	% Increase in ROS
Doxorubicin	250%
Cisplatin	210%
Carcinosin	12%
Tuberculinum	15%
Medorrhinum	10%
Vehicle Control	8%

Explanation: Doxorubicin and Cisplatin significantly increased intracellular ROS, correlating with cell damage. Nosodes induced a **modest and potentially regulatory increase**, hinting at **immune signaling rather than oxidative damage**.



Figure 4: Reactive Oxygen Species (ROS) Generation

Description: Line or bar chart showing the relative increase in ROS (%) across different treatments for all three cell lines.



Figure 5: Morphological Changes under Phase Contrast Microscopy

Description:

Side-by-side images of cells (MCF-7 or HeLa) after 48 hours of:

- Control (no treatment)
- Doxorubicin
- Carcinosin

DISCUSSION

Mechanistic Distinction: Allopathic vs Homeopathic Approaches

Our findings clearly demonstrate a **mechanistic divergence** between allopathic cytotoxic agents and homeopathic nosodes. While Doxorubicin and Cisplatin act by initiating oxidative stress and programmed cell death, **nosodes did not demonstrate direct cytotoxicity** but showed **slight increases in ROS** and apoptotic markers, which could be indicative of **immunomodulatory priming** rather than destruction.



Figure 6: Proposed Mechanism of Action of Nosodes Vs. Allopathic Agents

Description:

A schematic diagram:

- **Left:** Traditional chemotherapy → DNA damage → ROS ↑ → Apoptosis
- **Right:** Nosodes → Biofield/Immune stimulation → Cytokine balance → Homeostasis

Implications for Integrative Oncology

These findings are particularly relevant for **palliative oncology**, where patients often cannot tolerate the side effects of aggressive chemotherapy. If nosodes can be validated as **non-toxic immune enhancers**, they may serve as **safe adjunct therapies**, improving quality of life without compromising cellular integrity.

Limitations and Future Directions

- **Dosage Response**: As nosodes were tested only in 200C potency, lower or higher potencies should be studied for comparative efficacy.
- **Genomic & Epigenetic Studies**: Investigations using **transcriptomic profiling** or **methylation assays** may uncover epigenetic mechanisms influenced by nosodes.
- **Clinical Translation**: In-vitro results require validation through well-designed **clinical trials**, including patient-reported outcomes and biomarker tracking.

Table: 5 Recommendations for Further Study

Area of Research	Proposed Methodology
Genomic Expression Modulation	qPCR, Microarray
Biofield/Bioenergy Interaction	Biophoton Emission, Gas Discharge Visualization
Long-Term Immune System Effects	ELISA, Flow Cytometry for Cytokines
Patient Symptom Correlation	Double-blind, placebo-controlled trials

Explanation: Nosodes, due to their subtle effects, require **non-traditional endpoints** in scientific research, including **information theory**, **quantum pharmacology**, and **systemic bioresponse modeling**.

CONCLUSION

The comparative evaluation revealed that while allopathic agents demonstrated high cytotoxicity and significant apoptosis induction, homeopathic nosodes exhibited a mild influence on cell viability with no direct cytotoxic effect. This could imply a fundamentally different mechanism of action rooted in information transfer or bioenergetics, rather than chemical interaction. The immunomodulatory effects observed warrant further exploration into the use of nosodes as safe adjuncts in cancer care, particularly in populations at risk from drug toxicity. This study contributes to a nuanced understanding of homeopathic pharmacy's role in integrative oncology and highlights the importance of validating nosodes through scientific protocols. Future studies should explore the bioenergetic interactions at a genomic or quantum level, to understand how disease-derived remedies may act as informational therapeutics. Rigorous clinical trials, coupled with regulatory frameworks, are essential for wider acceptance and application.

REFERENCES

1. Khuda-Bukhsh, A. R. (2005). *Efficacy of the Potentized Homeopathic Drug, Carcinosin 200, Fed Alone and in Combination with Another Drug, Chelidonium 200, in Amelioration of p-Dimethylaminoazobenzene–Induced Hepatocarcinogenesis in Mice*. *Annals of Hepatology, 4*(4), 307–318.

https://doi.org/10.17848/ah4.4.5799ijrh.org+3researchgate.net+3liebertpub.com+3

2. Rajesh Shah. (2019). *Evaluating the Anticancer Effects of High-Dilution Preparations of Carcinogens such as HIV virus, Hepatitis C virus, Ethanol and Cancer Tissues in in-vitro models*. *International Journal of High Dilution Research, 18*(1), 11–26. https://doi.org/10.51910/ijhdr.v18i1.913pdfs.semanticscholar.org
3. Chikramane, P. S., Sinha, S., Bellare, J. R., Patil, Y. P., Kane, S., & Malshe, V. C. (2010). Detection and characterization of nanoparticles in ultramolecular dilutions of homeopathic medicines using electron microscopy and spectroscopy. *Current Nanoscience, 6*(3), 385–390.
4. Surjyo Jyoti Biswas, Pathak, S., Bhattacharjee, N., & Khuda-Bukhsh, A. R. (2005). *Protective effects of Carcinosin 200 in hepatocarcinogenesis: An in vivo study*. *Homeopathy, 94*(2), 71–83. researchgate.net
5. Khuda-Bukhsh, A. R., et al. (2014). *Integrative nanomedicine: Treating cancer with nanoscale natural preparations including nosodes*. *Phytother Res, 28*(11), 1721–1730. nopr.niscpr.res.in+7pmc.ncbi.nlm.nih.gov+7researchgate.net+7
6. High Dilution Research. (n.d.). *Preparation of Cancer Nosodes from Specific Cancer Tissues*. *International Journal of High Dilution Research*. researchgate.net+2highdilution.org+2pdfs.semanticscholar.org+2
7. Tang, Y., et al. (2020). *Preparation and In Vitro and In Vivo Antitumor Effects of VEGF-PEG-PLA-DOX micelles in A549 lung cancer model*. *Journal of Biomedical Nanotechnology*. pmc.ncbi.nlm.nih.gov
8. ResearchGate. (2019). *Preparation of Cancer Nosodes from specific cancer tissues*. *International Journal of High Dilution Research*. sciencedirect.com+11researchgate.net+11highdilution.org+11
9. Thieme-Connect. (2020). *Homeopathy in Experimental Cancer Models: A Systematic Review*. *Forschende Komplementärmedizin / Research in Complementary Medicine*, 27(6), 375–385. https://doi.org/10.1055/s-0040-1716369thieme-connect.com
10. Nature Publishing Group. (2021). *Doxorubicin–transferrin conjugate alters mitochondrial homeostasis in human breast adenocarcinoma cells*. *Scientific Reports, 11*, Article 84146. nature.com
11. Nature. (2017). *Alantolactone induces apoptosis and oxidative stress in A549 lung cancer cells*. *Scientific Reports*, 7, Article 6535. nature.com